Talk:Robert A. Bradway

Edits for consideration to the Robert_A_Bradway wiki page

 * What I think should be changed (include citations):

Hello, I am requesting consideration of edits to the Robert_A._Bradway Wiki page. He is the CEO of Amgen, a global biotech company based in Thousand Oaks, CA. I work for Amgen as the director of social & digital strategy. As part of an end-of-year audit of our social and digital presence, Bob's Wiki page is fairly sparse and we'd like to offer additional information and facts about his leadership in biotech, during the COVID-19 pandemic and other areas of possible interest to Wiki users.

EDIT #1 Requested:

UPDATE THIS SECTION: Bradway was the MD for banking department and corporate finance Europe, for Morgan Stanley in London. In 1985, he joined Morgan Stanley in New York as a health care industry investment banker. He then moved to London in 1990 where he served as head of Morgan Stanley's international health care investment banking activities. He subsequently, assumed responsibility for corporate finance management.[3]

Bradway joined Amgen in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010.[4] He was its president and chief operating officer from May 2010 to May 2012.[5] In 2011, he was appointed to the Amgen board of directors.[6]

Bradway serves on the board of directors of the Norfolk Southern Corporation and Boeing.[7] He gave the 2016 commencement speech at the Keck Graduate Institute, which is part of The Claremont Colleges.[8] He gave the 2017 commencement speech at the UCLA Anderson School of Management, where he serves on the board of trustees and on the board of the Leonard D. Schaeffer Center for Health Policy and Economics.[9]

He is the chairman of the CEO Roundtable on Cancer and a member of the American Heart Association CEO Roundtable.[10]

On October 1, 2020, Bradway testified before the House Oversight Committee and was excoriated by Rep. Katie Porter (D. Cal) for his considerable compensation. He and four other top Amgen executives earned a combined $124.2M over a three-year period spanning 2017–2019. [11]

TO THIS EDIT:

Bradway joined Morgan Stanley in New York in 1985 as a health care industry investment banker. In 1990 he moved to London, where he served as managing director of Morgan Stanley with responsibility for the firm's banking department and corporate finance activities in Europe. https://wwwext.amgen.com/about/leadership/senior-management/robert-a-bradway Bradway joined Amgen in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010. He was its president and chief operating officer from May 2010 to May 2012. In October 2011, he was appointed to the Amgen board of directors. Bradway was named CEO of Amgen in May 2012, and Chairman of the Board in January 2013. https://wwwext.amgen.com/about/leadership/senior-management/robert-a-bradway

Bradway is a member of the board of directors of The Boeing Company, serving on its Audit and Finance committees. https://www.boeing.com/company/general-info/corporate-governance.page He also serves on the board of trustees of the University of Southern California. https://pressroom.usc.edu/amgen-ceo-robert-bradway-named-usc-trustee/#:~:text=Bradway%20has%20been%20elected%20to,world's%20largest%20independent%20biotechnology%20company.&text=Bradway%20hAolds%20a%20bachelor's%20degree,business%20administration%20from%20Harvard%20University Bradway is the chairman of the CEO Roundtable on Cancer, a non-profit organization founded to bring solutions to cancer treatment and prevention. https://www.ceoroundtableoncancer.org/leadership-team He is a member of the American Heart Association CEO Roundtable, which is helping the Association meet its goal of improving the cardiovascular health of all Americans. https://ceoroundtable.heart.org/members/ Bradway is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors. https://www.phrma.org/en/About/Our-Leadership

During Bradway’s tenure as CEO, Amgen’s annual revenues have increased from $17.3 billion in 2012 to $23.4 billion in 2019, and annual R&D investment increased to $4.0 billion in 2019. In 2020, Amgen had some 22,000 employees and a presence in approximately 100 countries around the world, up from 56 countries in 2012. https://wwwext.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/investors/investors_2012_annualreport.ashx?la=en https://wwwext.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/fact-sheets/fact_sheet_amgen.ashx Amgen acquisitions since Bradway became CEO include Iceland-based deCODE Genetics in 2012 https://wwwext.amgen.com/newsroom/press-releases/2012/12/amgen-to-acquire-decode-genetics-a-global-leader-in-human-genetics, Onyx Pharmaceuticals in 2013 https://wwwext.amgen.com/newsroom/press-releases/2013/08/amgen-to-acquire-onyx-pharmaceuticals-for-$125-per-share-in-cash, and a 20.5% equity stake in Beijing-based BeiGene in 2020 https://wwwext.amgen.com/newsroom/press-releases/2020/01/amgen-commences-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china. Bradway was a keynote speaker at the World Medical Innovation Forum, held in Boston, Massachusetts in May 2015. He highlighted Amgen’s strategic focus on discovering, developing, manufacturing, and commercializing medicines for patients suffering from serious illnesses. He also discussed the need for collaboration among government, research institutions and industry peers to advance innovative medicines that benefit patients and society, and he addressed how Amgen is employing advances in genetic sequencing in its discovery research efforts. “Our focus is increasingly around human genetics, and using the tools of human genetics, to point us in the direction of new therapies for diseases,” Bradway said. https://wwwext.amgen.com/stories/2015/05/chairman-and-ceo-robert-bradway-speaks-at-world-medical-innovation-forum-in-boston

Speaking at the World Medical Innovation Forum May 2016, Bradway discussed advances in cancer research, Amgen’s growing presence in oncology and hematology, and the need for greater societal investment in the field. “There continue to be significant opportunities to invest in improvements in cancer therapy and prevention,” he said. “We have not yet reached a point of diminishing returns.” Bradway noted that collaboration among industry, academia, and government is necessary in order to advance cancer research at the level of basic biology. https://wwwext.amgen.com/stories/2016/05/amgen-senior-leaders-advance-discussion-on-cancer-at-2016-world-medical-innovation-forum

In June 2017, Bradway gave the keynote address at the commencement ceremony for graduates of the University of California, Los Angeles (UCLA) Anderson School of Management. https://wwwext.amgen.com/stories/2017/06/amgen-ceo-bob-bradway-gives-ucla-commencement-speech

In January 2019, Bradway spoke with CNBC’s Jim Cramer about Amgen’s new migraine treatment, as well as the company’s decision to reduce the list price of Repatha by 60% in the U.S. https://www.cnbc.com/2019/01/07/amgen-ceo-on-drug-price-cut-too-many-patients-struggled-to-pay.html

Statements on COVID-19 In a podcast interview with philanthropist and financier Michael Milken in April 2020, Bradway described Amgen’s response to the COVID-19 pandemic, including the company’s efforts to keep employees and their families safe, its support for affected communities, and its work to improve understanding of the virus through its deCODE Genetics subsidiary. He noted that deCODE’s research on coronavirus prevalence and transmission “underscores how important widescale testing is and how difficult it is to contain a virus like this, which is infectious and asymptomatic at the same time.” He added that “we need to make sure that while we're responding to COVID-19, we're not doing it at the expense of all these other patients, or we're going to create a secondary healthcare crisis that we never intended and that we could have prevented by striking that balance.” https://wwwext.amgen.com/stories/2020/04/milken-podcast---were-gaining-ground-fast

During a fireside chat with Fortune Editor-in-Chief Clifton Leaf at the magazine’s Brainstorm Health conference in July 2020, Bradway commented that “we’re witnessing an unprecedented amount of effort, energy, speed, and collaboration by the healthcare ecosystem” in trying to defeat COVID-19. He added that the pandemic has underscored the importance of improving our ability to predict and prevent disease. “All too often in our healthcare system,” he observed, “we wait until something is broken and then we try to fix it, and then try to return people back to their normal lives. We can do a lot better than that, and I think we should.” https://wwwext.amgen.com/stories/2020/07/bob-bradway-discusses-industrys-covid-19-response-at-fortune-conference

In September 2020, Bradway participated in the Financial Times’ annual U.S. Pharma and Biotech Summit. “The world now recognizes that we need innovation to get out from under the crush of this pandemic,” he noted. “It will take innovative vaccines and antivirals, as well as other innovative approaches, to allow us to prevent infection and manage the harm caused by the virus.” Bradway noted that “lots of creative work is being done by providers, payors, innovators, and the whole healthcare ecosystem to ensure that in tackling COVID-19 we don’t open the door to a secondary healthcare epidemic resulting from chronic diseases not being well managed.” https://wwwext.amgen.com/stories/2020/10/the-world-recognizes-we-need-innovation-to-defeat-covid-19---bradway-speaks-at-financial-times

Speaking at the Milken Global Conference in October 2020, Bradway noted that advances in human genetics are improving the ability to predict who is at greatest risk for chronic disease and to prevent the life-altering health events that often result from these diseases. He also discussed the biopharmaceutical industry’s contributions to the fight against COVID-19. “We are working to find answers to the larger question of what long-term consequences the virus will cause for people who are infected,” he said. “At the same time, the industry is working collaboratively to find new means to break the back of this pandemic, including vaccines, neutralizing antibodies, and anti-inflammatory medicines.” https://wwwext.amgen.com/stories/2020/10/bradway-urges-more-attention-to-predicting-and-preventing-chronic-disease

Statements on Racial and Societal Justice

Following the killing of George Floyd by Minneapolis police in May 2020, Bradway issued a statement noting that the incident “is part of a pattern that has become tragically clear in the U.S. and around the world. Equal justice and equal opportunity may be our ideals, but they are not yet our reality.” He declared the need to ensure that “all of our staff feel they belong at Amgen” and feel safe and welcome in our neighboring communities as well…. The time is right and the moment is now for all of us at Amgen to do our part in setting a new standard…. Let’s take inspiration from science and trust that progress, like knowledge, builds upon itself, incrementally improving on what exists today until the cumulative adds up to something profound. We are on a journey of a thousand miles,” Bradway concluded. “Let’s start taking some steps.” https://wwwext.amgen.com/stories/2020/05/ceo-bob-bradway-shares-perspective-on-death-of-george-floyd

In October 2020, Bradway spoke at Amgen’s annual Health Equity Summit, which brought together experts and leaders from across the healthcare industry to discuss racial disparities in health outcomes. “We need to try to maintain the energy that was created by the urgent problems of 2020 and to make sure that we continue to take the steps that are going to be needed in order to complete this journey,” he said. “This has to be a long-term commitment. It’s going to require resources — dollars and cents — but also some of our very best people over a long period of time for us to make progress.” https://wwwext.amgen.com/stories/2020/11/5-important-steps-for-advancing-health-equity

Statements on Health Care Reform: Speaking in May 2018 at the third annual Stanford Drug Discovery Symposium, Bradway called for moving from a healthcare system that is “designed to fix that which is broken” to one in which we “predict who is at risk of disease and intervene to prevent that disease from arising in the first place.” He noted that the U.S. already spends $3 trillion a year on healthcare – with $600 billion of that going toward cardiovascular disease. “With 10,000 people turning 65 every day in this country for the next 20 years,” he said, “that number is only going to rise, given that people over the age of 65 consume healthcare at a rate seven times higher than people under 65 do.” Bradway added that shifting to a new healthcare system will require the support of multiple stakeholders, including academia, industry, government, payers, and patient advocacy groups. He called on all those within the system to embrace change with a sense of urgency. https://wwwext.amgen.com/stories/2018/05/amgen-ceo-robert-bradway-calls-for-healthcare-system-that-predicts-and-prevents-serious-illnesses

Speaking at the Piper Jaffray Heartland Summit in June 2019, Bradway addressed the growing demand for healthcare globally and the opportunities and challenges this demand is creating. “Will there be a greater demand for healthcare in 20 years? Absolutely. The demographic trends are irrefutable – an aging population around the world, a rapidly growing global middle class, increased urbanization.” Bradway noted that these demographic trends will lead to a dramatic rise in serious illnesses like cancer and heart disease – and a corresponding growth in demand for innovative solutions to help people suffering from these illnesses live longer, healthier lives. The challenge, he said, is “whether and how society will pay for the innovative healthcare solutions that are so desperately needed – today and even more so in the future.” To address this challenge, healthcare systems around the world need to move from “fixing what is broken to predicting who is at risk of a serious health event and intervening to prevent that event from occurring in the first place.” https://wwwext.amgen.com/stories/2019/06/amgen-ceo-bob-bradway-advocates-for-healthcare-systems-that-predict-and-prevent-serious-illness

Accolades: In September 2013 Bradway was named one of STEMConnector’s “100 CEO Leaders in STEM.” The publication recognized Bradway as being among the senior corporate executives who have best demonstrated leadership and advocacy of science, technology, engineering and math (STEM) education and the need for a STEM workforce. https://www.amgen.com/stories/2013/09/robert-bradway-named-a-top-100-ceo-leader-in-stem#:~:text=Bradway%2C%20Chairman%20and%20Chief%20Executive,%2C%20technology%2C%20engineering%20and%20math%20(

In September 2016, Bradway accepted the 2016 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research on behalf of Amgen. Bestowed by the Cancer Research Institute, the award honored Amgen and Bradway for making a significant impact in the field of immuno-oncology. https://wwwext.amgen.com/stories/2016/10/ceo-robert-bradway-accepts-grace-award

Bradway was named “Best CEO” by Institutional Investor magazine in its 2021 All-America Executive Team Rankings. The All-America Executive Team survey took place amid the COVID-19 pandemic, capturing critical feedback of corporate performance during exceptional socioeconomic and market stress. The result was one of the survey's most significant voter turnouts, with over 3,000 money managers and buy-side analysts, and almost 500 sell-side researchers providing their candid feedback. https://www.globenewswire.com/news-release/2020/11/10/2123823/0/en/Institutional-Investor-Publishes-2021-All-America-Executive-Team-Rankings.html

Edit #2 for consideration: In this paragraph below: On October 1, 2020, Bradway testified before the House Oversight Committee and was excoriated by Rep. Katie Porter (D. Cal) for his considerable compensation. He and four other top Amgen executives earned a combined $124.2M over a three-year period spanning 2017–2019. [11]

Change the word excoriated to questioned.

On October 1, 2020, Bradway testified before the House Oversight Committee and was questioned by Rep. Katie Porter (D. Cal) about his compensation. He and four other top Amgen executives earned a combined $124.2M over a three-year period spanning 2017–2019.


 * Why it should be changed:

Hello, I am requesting consideration of edits to the Robert_A._Bradway Wiki page. He is the CEO of Amgen, a global biotech company based in Thousand Oaks, CA. I work for Amgen as the director of social & digital strategy. As part of an end-of-year audit of our social and digital presence, Bob's Wiki page is fairly sparse and we'd like to offer additional information and facts about his leadership in biotech, during the COVID-19 pandemic and other areas of possible interest to Wiki users.

Secondly, we think the word choice in the last sentence (excoriated) editorializes the exchange and respectfully ask consideration of changing the word to questioned.

I will submit a headshot of Bob separately. Thank you for your consideration of these edits. I can be reached on my Amgen email at srucci@amgen.com.

107.185.216.50 (talk) 00:25, 5 January 2021 (UTC)Susan Rucci, Director, Social & Digital Strategy, Amgen


 * I agree that the term excoriated editorializes the article, and I have corrected it. The rest of the suggested edits are, in my opinion, of limited interest to the general public, and give the impression of self promotion per WP:AUTOBIO (in this case, AUTOBIO by proxy), or just advertising for the Amgen organization.  Per WP:NOTE, WP:IS and WP:RS, I oppose all other edits to the article in this request. Ferkijel (talk) 22:23, 30 March 2021 (UTC)
 * The changes in the first two paragraphs were reasonable, and I've made them. Most of the remaining changes are far too wordy, non-neutral and promote Amgen or Bradway. I've marked the ones that are least acceptable. Some of the others be added to the article, but they'll have to be much more concise and neutrally worded. For example, of the paragraph about the Institutional Investor award, I'd use the first sentence, no more. The Piper Jaffray Summit: one sentence that mentions the summit, then a quote of no more than two sentences, but preferably one sentence. Please remember that Wikipedia articles are based on independent secondary sources, not primary sources related to the article subject. An article in Forbes or The Wall Street Journal is much better for our purposes than a press release or a bio on a corporate webpage. Thanks. BlackcurrantTea (talk) 00:45, 14 April 2021 (UTC)

COI Edit Request - July 2022
Hi there! I have a COI: Amgen, Robert Bradway's employer, is a client of my employer, Porter Novelli. Requesting some edits to this article, which I've broken out by section below.

Career

 * Add to end of section:
 * During Bradway’s tenure as CEO, Amgen's annual revenue increased from $17.3 billion in 2012 to $26 billion in 2021, and annual R&D investment increased to $4.2 billion in 2020. Bradway oversaw the acquisition of Iceland-based DeCODE Genetics in 2012, Onyx Pharmaceuticals in 2013, and a 20.5% equity stake in Beijing-based BeiGene in 2020.

Public statements

 * Within "Career", add a new subsection titled "Public statements". The two commencement addresses in the third paragraph of "Career" can be moved here, as well as new content:
 * Bradway was a keynote speaker at the 2015 World Medical Innovation Forum. In June 2017, he gave the keynote address at the commencement ceremony for graduates of the University of California, Los Angeles Anderson School of Management. Bradway was a speaker at Fortune magazine's Brainstorm Health virtual conference in June 2020.


 * Following the murder of George Floyd in May 2020, Bradway issued a statement condemning the murder as "senseless" and pledging to address racial inequality at Amgen, stating, "Let's take inspiration from science and trust that progress, like knowledge, builds upon itself, incrementally improving on what exists today until the cumulative adds up to something profound."

JZindler (talk) 19:29, 6 July 2022 (UTC)
 * These edits have been made and incorporated into the article. The edit request is therefore closed. Go4thProsper (talk) 08:09, 6 August 2022 (UTC)


 * Thank you, much appreciated!! JZindler (talk) 20:09, 10 August 2022 (UTC)